Overview

* Prime Medicine ( PRME ) Q3 net loss narrows to $50.6 mln from $52.5 mln last year

* Operating expenses rise due to increased R&D costs, offset by lower G&A expenses

* Company advances liver-targeted programs, clinical data expected in 2027

Outlook

* Prime Medicine expects to file IND/CTA for WD in H1 2027

* Initial clinical data for WD and AATD expected in 2027

Result Drivers

* R&D expenses were $44.0 million for the three months ended September 30, 2025, as compared to $40.3 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.32

Q3 Net -$50.58

Income mln

Q3 -$53.97

Income mln

from

Operatio

ns

Q3 $55.20

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Prime Medicine Inc ( PRME ) is $7.00, about 40.3% above its November 6 closing price of $4.18

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)